Abstract

Provided is a genome extraction microfluidic chip having the advantage that genome extraction can be performed without being constrained in terms of personnel and location, and the advantage that the process of genome extraction can be performed rapidly without human intervention when a voice command is received. According to an aspect of the present invention, there is provided a genome extraction microfluidic chip including: a genome extraction member; a flexible film disposed under the genome extraction member; and an interface layer disposed under the flexible film and including a flow channel corresponding to the valve.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

Abstract

According to an aspect of the present invention, a multi-gantry low-dose radiation apparatus may be provided and comprises: a main body unit in which a bed on which a patient lies and receives treatment is formed in a longitudinal direction; a radiation gantry installed on the upper side of the main body unit to irradiate a plurality of low-dose radiation rays toward the body of the patient in a direction of the inner periphery of a ring gate while moving along a rail unit; a gantry accommodation unit at one end of the main body unit to accommodate the radiation gantry in a standby state for operation; and a control unit that is installed on one side of the gantry accommodation unit to check the condition of the patient by using input patient information, sets a treatment direction, and then controls the operation of the radiation gantry, wherein the radiation gantry includes a plurality of radiation gantries that are installed in the longitudinal direction of the main body unit and are operated in conjunction or individually.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

The present invention relates to a virus-like particle combination vaccine comprising influenza A virus antigen protein HA, NA or M2e5x. A recombinant universal influenza-virus-like particle vaccine for protection against infection by influenza A virus (H1N1, H3N2 and H5N1) and influenza B virus (B/Victoria lineages) has been developed by preparing a virus-like particle vaccine expressed by a combination of: hemagglutinin (HA) and neuraminidase (NA) antigen proteins of 2020/2021 influenza viruses of A/Guangdong-Maonan/SWL1536/2019 (H1N1) and A/Hong Kong/2671/2019 (H3N2), which were recently predicted by the World Health Organization (WHO); and heterologous tandem M2e repeat (M2e5x) antigen proteins of conventional human, swine, and avian influenza viruses. The virus-like particle vaccine having high efficacy against various influenza, obtained by developing, on the basis of the present invention, a vaccine exhibiting high immunogenicity, can reduce infection and mortality caused by influenza A and B viruses during a global pandemic.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

A curved mirror of the present invention comprises: a through-hole through which electrons, which are incident on a sample, pass; and a collection surface, which is made of a curved surface so as to encompass the sample, thereby collecting photons emitted from the sample by means of the penetrating electrons, wherein the through-hole is formed on the collection surface. Therefore, in the present invention, the curved mirror having a structure of encompassing the sample is applied so that the collecting performance of the photons emitted from the surface of the sample can be enhanced.

IPC Classes  ?

• G01N 23/2273 - Measuring photoelectron spectra, e.g. electron spectroscopy for chemical analysis [ESCA] or X-ray photoelectron spectroscopy [XPS]
• G01N 23/2204 - Specimen supports therefor; Sample conveying means therefor

Abstract

in vitroin vivoin vivo, is stable in biological environments, can specifically target and visualize synovial cells and synovial areas in the body, and thus can be used in drug development and medical fields and be effectively used in the diagnosis and treatment of synovium-associated diseases.

IPC Classes  ?

• C07K 5/093 - Tripeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61K 49/00 - Preparations for testing in vivo

Abstract

Provided is a rotary microfluidic device which can reduce the time, cost, and labor required to synthesize nanoparticles. Provided according to an aspect of the present invention is a rotary microfluidic device comprising: a reaction chamber; an injection chamber connected to the reaction chamber and including one or more sub-chambers; and one or more connection parts connecting the respective sub-chambers to each other and connecting the reaction chamber and the injection chamber to each other, wherein each of the connection parts includes a passive valve.

IPC Classes  ?

• B01J 19/00 - Chemical, physical or physico-chemical processes in general; Their relevant apparatus
• B01J 2/14 - Processes or devices for granulating materials, in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in rotating dishes or pans
• B22F 9/24 - Making metallic powder or suspensions thereof; Apparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
• G01N 21/65 - Raman scattering

Abstract

222 synthase-1 (mPGES-1), and can be used as a pharmaceutical composition for treating mPGES-1-mediated diseases.

IPC Classes  ?

• C07D 235/18 - Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Abstract

According to one embodiment of the present invention, provided is a low-dose radiation treatment system for treating dementia and chronic inflammation according to the form of photon energy beam emission, the system comprising: a low-dose radiation treatment device which has, in a device body, a treatment bed on which a patient lies and receives treatment, and which has, in the device body, a plurality of carbon nanotube radiation sources provided on the inner circumference of a ring-shaped gate, so as to form a radiation gantry so that therapeutic radiation is emitted toward the body of the patient; and a control unit, which uses input patient information so as to examine the condition of the patient, sets treatment directions, and then controls the operation of the low-dose radiation treatment device so as to perform radiation treatment, wherein pulsed-beam-type carbon nanotube radiation sources are provided on the inner circumference of the radiation gantry, and the control unit controls the radiation beam irradiation time (beam on-off time) of the carbon nanotube radiation sources and the radiation beam irradiation interval between carbon nanotube radiation sources, the beam irradiation interval being controlled to be cell damage recovery time (DNA repair time) in which DNA damage in normal cells can be repaired.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

According to an aspect of the present invention, there may be provided a low-dose radiation therapy system for the treatment of dementia and chronic inflammation according to a photon energy beam emission form, the low-dose radiation therapy system comprising: a low-dose radiation therapy device that forms, in the body of the device, a treatment bed on which a patient lies down and receives treatment and that forms, in the body of the device, a radiation gantry having a plurality of carbon nanotube ray sources mounted on the inner circumferential surface of an annular gate and radiating treatment radiation toward the body of the patient; and a control unit that checks the condition of the patient by using input patient information, sets a treatment direction, and then controls the operation of the low-dose radiation therapy device to perform radiation therapy, wherein the carbon nanotube ray sources of a pulsed beam type are mounted on the inner circumferential surface of the radiation gantry, and the control unit controls a beam on-off time of radiation of the carbon nanotube ray sources and a beam radiation interval of radiation between the carbon nanotube ray sources, wherein the beam radiation interval is controlled to a DNA repair time in which DNA damage in normal cells can be repaired.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

An aspect of the present invention may provide a capsule-type low-dose radiation treatment device having a wheelchair interworking structure, wherein a capsule door configured to form the front surface of a radiation treatment capsule for providing a radiation-shielded cocoon-shaped treatment chamber is operated to be fully opened forwards or closed, and a treatment bed installation portion for mounting a radiation gantry is coupled to the rear surface of the capsule door and is operated while interworking with the capsule door. When the capsule door is fully opened, a patient boarding gate is secured by using a lateral space between the treatment capsule and the capsule door. The patient reaches the location of the treatment bed installation portion while sitting on the wheelchair through the patient boarding gate, and is directly transferred from the wheelchair to the treatment bed installation portion.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

The present invention relates to use of a microorganism of the genus Euglena for: preventing, ameliorating or treating blood dyscrasia; and preventing, ameliorating or treating cancer. The microorganism of the genus Euglena according to the present invention was confirmed to restore blood cells reduced by administration of an anticancer drug to a normal level, without affecting the spleen immune cell population. The microorganism of the genus Euglena was also confirmed to significantly increase the production of granulocyte/macrophage colony-stimulating factors underlying the hematopoietic response. This means that the microorganism of the genus Euglena according to the present invention promotes hematopoiesis, and thus can be used in the fields of blood dyscrasia and cancer-related treatment in various ways.

IPC Classes  ?

• A61K 36/02 - Algae
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 35/00 - Antineoplastic agents
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Abstract

The present invention relates to a non-powered electrostimulation application unit, a manufacturing method thereof, and an application method thereof. More specifically, the present invention relates to a non-powered electrostimulation application unit comprising an electric field forming part which itself forms an electric field without separate external power supply, wherein the electric field forming part is attached directly to a subject or attached to a container in which the subject is contained, so as to apply electrical stimulation to the subject.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61N 1/30 - Apparatus for iontophoresis or cataphoresis
• A61N 1/04 - Electrodes

Abstract

Disclosed are an image encoding/decoding method and a device, and a recording medium for storing a bitstream. An image decoding method according to an embodiment may comprise the steps of: reconstructing an encoding mode of a unit block; reconstructing one or more sub-blocks of the unit block; reconstructing the unit block from the one or more sub-blocks on the basis of the encoding mode; and reconstructing an image on the basis of the unit block, wherein the encoding mode includes at least one among a first mode, in which the unit block is divided into two or more sub-blocks using a prescribed scanning method, a second mode, in which sub-blocks of a lower resolution are generated from the unit block, and a third mode, in which the unit block is sampled and two or more sub-blocks are generated.

IPC Classes  ?

• H04N 19/119 - Adaptive subdivision aspects e.g. subdivision of a picture into rectangular or non-rectangular coding blocks
• H04N 19/132 - Sampling, masking or truncation of coding units, e.g. adaptive resampling, frame skipping, frame interpolation or high-frequency transform coefficient masking
• H04N 19/176 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using adaptive coding characterised by the coding unit, i.e. the structural portion or semantic portion of the video signal being the object or the subject of the adaptive coding the unit being an image region, e.g. an object the region being a block, e.g. a macroblock
• H04N 19/13 - Adaptive entropy coding, e.g. adaptive variable length coding [AVLC] or context adaptive binary arithmetic coding [CABAC]
• H04N 19/124 - Quantisation
• G06T 9/00 - Image coding
• G06N 3/045 - Combinations of networks

Abstract

The present invention relates to a display pixel circuit using a ferroelectric thin film transistor and a driving method thereof. More specifically, the present invention relates to: a display pixel circuit which selectively applies a volatile switch function and a non-volatile memory function by using a plurality ferroelectric thin film transistors each comprising a ferroelectric gate insulating layer with a high dielectric constant (high-k); and a method for driving same.

IPC Classes  ?

• G09G 3/3225 - Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix using controlled light sources using electroluminescent panels semiconductive, e.g. using light-emitting diodes [LED] organic, e.g. using organic light-emitting diodes [OLED] using an active matrix
• H01L 27/32 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including components using organic materials as the active part, or using a combination of organic materials with other materials as the active part with components specially adapted for light emission, e.g. flat-panel displays using organic light-emitting diodes

Abstract

The present invention relates to a fluorescent probe compound for detecting homocysteine, and use thereof, wherein the fluorescent probe compound prepared according to the present invention enables homocysteine present in in vitro plasma and feces to be detected within a short period of time without interference from other biomolecules, and thus has very high usability with respect to bio-derived materials and can be effectively used in early diagnosis identification of glioblastoma.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

CodonopsisAsterPolygalaCodonopsisAsterPolygalaPolygala sp. plants; and a method for preventing and treating COVID-19 by using the pharmaceutical composition.

IPC Classes  ?

• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 36/344 - Codonopsis
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/69 - Polygalaceae (Milkwort family)
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a composition for prevention or treatment of neuroinflammation, containing a Daphne genkwa flower bud extract as an active ingredient. According to the present invention, the Daphne genkwa flower bud extract of the present invention exhibits anti-inflammatory activity in nerve cells and thus has an effect of inhibiting neuroinflammation, inhibits (over)activation of microglia, and prevents neuronal loss and promotes the proliferation of nerve cells, thereby protecting nerves, and thus may be used for the use of reducing neuroinflammatory disease, neurodegenerative disease, or microglial activation.

IPC Classes  ?

• A61K 36/83 - Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

An embodiment of the present invention relates to: a boron compound in which specific nitrogen is substituted with oxygen or sulfur; and an organic light-emitting device including same and, more specifically, to a boron compound and an organic light-emitting device including same, wherein the boron compound can realize a deep-blue wavelength with improved delayed fluorescence properties along with improved narrow full-width at half maximum properties by shifting a short wavelength due to a shortened conjugation length, through a chemical structure in which oxygen or sulfur having greater electronegativity than nitrogen is positioned around boron in a delayed fluorescence structure in a multi-resonant form including diboron.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)

Abstract

The present invention provides a head acupoint laser stimulator comprising: a case part formed in a dome shape; a plurality of laser generation units, which are arranged inside the case part, emit laser needles at acupoints distributed on the head so as to stimulate same, and have a plurality of lasers arranged to be separated from each other; and a laser control unit for controlling the plurality of laser generation units. The head acupoint laser stimulator according to the present invention emits laser needles generated by the plurality of laser generation units so as to stimulate the acupoints distributed on the head and influence the in-body meridian system, and thus can exhibit a therapeutic effect similar to that of acupuncture. In addition, laser needles are used so that stability according to a non-pharmacological therapy is ensured and a contactless procedure is performed so that a user has no pain or bleeding during the procedure, and a metal needle is excluded from the device so that concerns about infection by other diseases can also be solved, and thus the user can be both relaxed and comfortable.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61N 5/067 - Radiation therapy using light using laser light
• A61H 39/00 - Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture

Abstract

The present invention provides a composition for preventing and treating inflammatory edema due to surgery and plastic surgery, the composition comprising an extract of Phaseolus angularis Wight as an active ingredient. Administering the extract of Phaseolus angularis Wight according to the present invention after administering LPS to an animal model and causing an inflammatory response was found to inhibit inflammation mediators and IL-1 beta mRNA, IL-6 mRNA, TNF-alpha and IL-4 expressed in the inflammatory response. Also, the extract of Phaseolus angularis Wight was found to increase IL-10 expression, which is involved in early inflammatory response, and inhibit IL-18, which is involved in acquired immune response, decrease the amount of edema, observed with the naked eye, in the soles of the animal model and decrease the amount of cell infiltration in sole tissue, and thus was found to be effective for alleviating and treating inflammatory edema. Therefore, the present invention can be used in useful enterprises associated with inflammatory edema.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• A61P 7/10 - Antioedematous agents; Diuretics

Abstract

The present invention provides a composition for prevention and treatment of arthritis-induced inflammatory edema, comprising a Lysimachia christinae Hance extract as an active ingredient. For the Lysimachia christinae Hance extract of the present invention, it has been identified that, when an inflammatory response is induced in an animal model by administering LPS, and then the Lysimachia christinae Hance of the present invention is administered, IL-1 beta mRNA, IL-6 mRNA, TNF-alpha, IL-4 expressed in an inflammatory response and inflammatory mediator material are inhibited. In addition, it has been identified that IL-10 mRNA involved in an initial inflammatory response is increased, IL-18 mRNA involved in an adaptive immune response is inhibited, edema of the sole of the foot of the animal model is also visibly reduced to the naked eye, and, as a result of checking foot sole tissue, infiltrated cells are also reduced, and thus, by identifying that the present invention is effective for reduction and treatment of inflammatory edema, the present invention may be used in relevant useful businesses.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61P 7/10 - Antioedematous agents; Diuretics

Abstract

A survey-based diagnosis method and a system therefor are provided. The survey-based diagnosis method according to several embodiments of the present disclosure enables a diagnosee to be diagnosed on the basis of response information about the diagnosee with respect to a plurality of survey questions. The plurality of survey questions can include questions for diagnosing an energy and blood generation function, an energy and blood circulation function, and an energy and blood balance adjustment function, and the health condition of the diagnosee can be accurately diagnosed by using these questions. In addition, a quick and convenient oriental medicine diagnosis service can be provided using a questionnaire technique.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 20/90 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
• G06N 3/08 - Learning methods

Abstract

Provided is a scan driver of a display device, wherein the scan driver may include a plurality of stages. Each stage includes: a scan unit which includes a plurality of scan transistors and outputs a scan signal for driving a scan line using the plurality of scan transistors; and a memory unit which receives a start signal, a data voltage, and a scan control signal, and selectively outputs, to the scan unit, at least one among the start signal and the data voltage as a scan start signal. The start signal may include an initial start signal and a scan signal of a previous stage. In a programming mode, the memory unit outputs the start signal to the scan unit as the scan start signal, and in a selective scan driving mode, does not output the start signal and outputs the data voltage to the scan unit as the scan start signal.

IPC Classes  ?

• G09G 3/3266 - Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix using controlled light sources using electroluminescent panels semiconductive, e.g. using light-emitting diodes [LED] organic, e.g. using organic light-emitting diodes [OLED] - Details of drivers for scan electrodes

Abstract

A method, a device, and a recording medium for image encoding/decoding are disclosed. In embodiments, hidden vector movement and hidden vector compensation for image compression based on a neural network are described. Hidden vector movement is a method for improving the efficiency of entropy encoding by moving a component of a hidden vector which is difficult to estimate by a probability model of the hidden vector. Hidden vector compensation is a method for reducing image quality degradation of a reconstructed image by compensating for information lost by hidden vector movement. A reconstructed image having a higher image quality can be provided by hidden vector movement and hidden vector compensation.

IPC Classes  ?

• G06T 9/00 - Image coding
• H04N 19/124 - Quantisation
• H04N 19/13 - Adaptive entropy coding, e.g. adaptive variable length coding [AVLC] or context adaptive binary arithmetic coding [CABAC]
• H04N 19/184 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using adaptive coding characterised by the coding unit, i.e. the structural portion or semantic portion of the video signal being the object or the subject of the adaptive coding the unit being bits, e.g. of the compressed video stream
• G06N 3/047 - Probabilistic or stochastic networks
• G06N 3/08 - Learning methods

Abstract

An unmanned aerial vehicle and a method for supporting task offloading are disclosed. An unmanned aerial vehicle for supporting task offloading according to an embodiment may comprise: a communication unit that communicates with at least one of a user terminal, one or more different unmanned aerial vehicles, and a base station; and a control unit connected to the communication unit, wherein the control unit receives a task from the user terminal via the communication unit, and determines whether to offload some or all tasks to be performed on the basis of at least one of the computing capacity of the unmanned aerial vehicle, the computing capacity of the one or more different unmanned aerial vehicles, the data transfer speed for the one or more different unmanned aerial vehicles, the computing capacity of the base station, and the data transfer speed for the base station.

IPC Classes  ?

• B64C 39/02 - Aircraft not otherwise provided for characterised by special use
• B64D 47/00 - Equipment not otherwise provided for
• G06F 9/48 - Program initiating; Program switching, e.g. by interrupt
• G06F 9/50 - Allocation of resources, e.g. of the central processing unit [CPU]
• H04L 67/59 - Providing operational support to end devices by off-loading in the network or by emulation, e.g. when they are unavailable

Abstract

Disclosed are a blockchain-based federated learning system supporting structured transparency and an operation method thereof. The federated learning system according to an embodiment may comprise: one or more local clients that generate local learning models by using different types of local training data; a central server that generates a federated learning model by receiving the respective local learning models from the one or more local clients; a task publisher that publishes, in a smart contract, a model structure of a federated learning task to be performed by the one or more local clients and the central server; a file system that shares and stores the local learning models and the federated learning model, and generates hashes for the local learning models and the federated learning model; and a blockchain network that stores the smart contract, the hashes for the local learning models, and the hash for the federated learning model.

IPC Classes  ?

• G06N 20/20 - Ensemble learning
• H04L 9/00 - Arrangements for secret or secure communications; Network security protocols
• H04L 9/06 - Arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems

Abstract

A device-to-device knowledge transmission method using a proxy dataset in federated learning, according to the present invention, comprises the steps of: downloading proxy data; generating, by a management server, management server output knowledge by machine learning input data by using a first artificial neural network function; generating, by first to nth devices, a plurality of pieces of device output knowledge by machine learning input data by using a second artificial neural network function; and if a preset number of times is reached, stopping the machine learning, transmitting the management server output knowledge to the first to nth devices, and transmitting the plurality of pieces of device output knowledge to the management server.

IPC Classes  ?

• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 3/08 - Learning methods
• G06N 20/20 - Ensemble learning

Abstract

A disclosed electric vehicle charging infrastructure power distribution system according to one embodiment of the present invention may comprise: a charging information collection unit which is provided at each of a plurality of charging stations and which collects charging-related information from an electric vehicle that is to be charged with power at the charging station; a central control unit which receives the charging-related information from a plurality of charging information collection units and which determines a power assignment amount of each charging station by using an artificial intelligence model on the basis of the charging-related information collected at each charging station; and an energy distribution unit for distributing, on the basis of the determined power assignment amount, power amounts assigned to the plurality of charging stations.

IPC Classes  ?

• G06Q 50/30 - Transportation; Communications
• B60L 53/66 - Data transfer between charging stations and vehicles
• B60L 53/30 - Constructional details of charging stations
• G06N 20/00 - Machine learning
• G06N 3/02 - Neural networks

Abstract

The present invention relates to a composition for relieving or treating pain, a method for relieving or treating pain by using same, and a method for screening for a pain-relieving substance. It has been confirmed that pain can be relieved by regulating the cerebellum, whose role in pain has not been known so far, by using the pharmaceutical composition and the method for relieving pain, according to the present invention. Therefore, the cerebellum can be used as a new treatment target for pain relief through the pharmaceutical composition and the method for relieving pain, according to the present invention. It has also been confirmed that, even when the cerebellum is used as a target for pain according to the present invention, there is no impact on motor function. Thus, the pharmaceutical composition and the method can be effectively used in practice in relieving or treating pain.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/42 - Oxazoles
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

Provided are: an anti-inflammatory composition containing an extract of a gold nanoparticle-peanut sprout as an active ingredient; and the like. The extract of a gold nanoparticle-peanut sprout, according to the present invention, exhibits the effects of inhibiting NO production, inhibiting IL-6 production, inhibiting TNF-α production, and inhibiting ROS production, and thus has anti-inflammatory effects. Therefore, it is expected that the present invention is effectively used as a pharmaceutical composition, food composition, or cosmetic composition having physiological activities, and the like.

IPC Classes  ?

• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• A61K 9/14 - Particulate form, e.g. powders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to an image encoding method based on the periodicity of a phase signal. The image encoding method comprises the steps of: generating a prediction signal for a current signal; decoding a differential signal from a bitstream; generating an initial restored signal on the basis of the prediction signal and the differential signal; and generating a restored signal converted so as to have a magnitude value within a preset range by converting a value of the initial restored signal, wherein the converted restored signal is generated on the basis of a period of a signal, and the preset range is a periodic range of the signal.

IPC Classes  ?

• G03H 1/08 - Synthesising holograms
• H04N 19/597 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using predictive coding specially adapted for multi-view video sequence encoding
• H04N 19/147 - Data rate or code amount at the encoder output according to rate distortion criteria

Abstract

The present invention relates to a vaccine adjuvant composition comprising an Agrimonia pilosa extract and a Galla rhois extract, wherein the vaccine adjuvant composition can increase the effect of virus vaccines and can thus be effectively used as an adjuvant for increasing the immune response of various vaccines, such as SARS-CoV-2 virus and influenza virus vaccines.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a silicone polymer compound, a method for preparing same, a composition for transdermal delivery comprising same, and an anti-cancer composition comprising same, wherein a cyclic silane is used as a monomer, and the molecular weight, viscosity, contact angle, moisture content, drug encapsulation ratio, and release behavior of a synthesized silicone polymer compound can be controlled by controlling polymerization conditions such as the type of initiator, ratio of initiator to monomer, and polymerization temperature, and the synthesized silicone polymer compound can thus be used as a transdermal delivery system loaded with a drug and various active substances. In addition, by encapsulating an anticancer agent in the silicone polymer compound of the present invention, the effect of the anticancer agent can be enhanced, and the silicone polymer compound can thus also be utilized for an anticancer use.

IPC Classes  ?

• C08G 77/04 - Polysiloxanes
• C08G 77/06 - Preparatory processes
• C08G 77/08 - Preparatory processes characterised by the catalysts used
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

According to an aspect of the present invention, provided is a low-dose ionized radiation therapy apparatus comprising: a bed on which a patient lies and receives therapy; an apparatus body on which the bed is mounted so as to reciprocate in the lengthwise direction; a radiation gantry which has an annular gate formed on the upper side of the apparatus body so as to allow the bed to pass through the center thereof and which enables a plurality of therapeutic radiations to be emitted toward the body of the patient from the inner circumference direction of the gate.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

The present invention relates to a method for cryopreservation of stem cells using an elastin-like artificial extracellular matrix. The stem cell cryopreservation technique using an elastin-like artificial extracellular matrix according to the present invention enjoys the advantages of using the RGD motif adherent to the integrin expressed by human embryonic stem cells to mimic the in vivo environment of human embryonic stem cells, and at the same time, employing an elastic protein structure, which is an extracellular substrate absent in the early human embryonic stem cell development environment, to make no unnecessary stimuli to the differentiation mechanism of embryonic stem cells, and thus can be advantageously used for developing cryopreservation products for research on science and technology using stem cells, cell therapy products, and products for cryopreservation.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• C12N 5/073 - Embryonic cells or tissues; Foetal cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Disclosed are a product shape design method using contact body pressure analysis and a device therefor. The product shape design method according to an embodiment of the present invention comprises the steps of: receiving body scan data of a subject; generating a virtual subject corresponding to the subject on the basis of the received body scan data; contacting the generated virtual subject with a preconfigured product shape to be designed and calculating contact pressure generated by contact of the virtual product and the product shape; and designing the product shape by changing the product shape on the basis of the calculated contact pressure.

IPC Classes  ?

• G06F 30/23 - Design optimisation, verification or simulation using finite element methods [FEM] or finite difference methods [FDM]
• G06F 30/17 - Mechanical parametric or variational design
• G06T 17/00 - 3D modelling for computer graphics
• G06F 111/16 - Customisation or personalisation
• G06F 119/14 - Force analysis or force optimisation, e.g. static or dynamic forces
• G06F 111/04 - Constraint-based CAD

Abstract

Disclosed is a fiber manufacturing device comprising: a chamber unit; a grip unit placed in the inner space of the chamber unit and gripping a material that is to be processed; a heating unit located below the grip unit and applying heat to the material; and a winding unit located under the heating unit and pulling a material, which has ductility due to heat, to process same into fibers.

IPC Classes  ?

• D02J 1/22 - Stretching or tensioning, shrinking or relaxing, e.g. by use of overfeed and underfeed apparatus, or preventing stretch
• D02J 13/00 - Heating or cooling the yarn, thread, cord, rope, or the like, not specific to any one of the processes provided for in this subclass
• B25J 11/00 - Manipulators not otherwise provided for
• B25J 13/00 - Controls for manipulators
• B25J 9/02 - Programme-controlled manipulators characterised by movement of the arms, e.g. cartesian co-ordinate type

Abstract

Provided is an integrated microcapillary electrophoresis system that can improve user convenience and can be applied to various on-site molecular diagnostic fields. One embodiment of the present invention is an integrated microcapillary electrophoresis system, and the provided integrated microcapillary electrophoresis system comprises: a microcapillary electrophoresis chip; a mobile phone that supplies voltage for electrophoresis to the microcapillary electrophoresis chip; and a boosting means that boosts power supplied from the mobile phone so as to supply the boosted voltage to the microcapillary electrophoresis chip.

IPC Classes  ?

• G01N 27/447 - Systems using electrophoresis

Abstract

Provided is a microfluidic chip capable of IoT-based on-site diagnosis. One embodiment of the present invention provides a microfluidic chip for diagnosis, the microfluidic chip comprising: a dissolution chamber (100) in which a sample is injected and then dissolved; a mixing chamber (200) in which the solution is received from the dissolution chamber (100) and then mixed with a polymerase; and reaction chambers (300) in which the solution is received from the mixing chamber (200) and then mixed with a primer, and then undergoes an amplification reaction, wherein there are at least two of the reaction chambers (300), and the amplification reaction of the solution received from the mixing chamber (200) proceeds in isolation in each of the reaction chambers (300).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• B01L 7/00 - Heating or cooling apparatus; Heat insulating devices
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
• G16Y 40/10 - Detection; Monitoring
• G16Y 40/20 - Analytics; Diagnosis

Abstract

A light source device according to one embodiment of the present invention outputs an extreme ultraviolet light source on the basis of an electron beam, the light source device comprising: a chamber; an electron beam emission unit that generates an electron beam inside the chamber and includes a cathode electrode and a plurality of emitters including a carbon-based material and disposed spaced apart from each other on the cathode electrode; and an anode electrode which is located inside the chamber so as to be spaced apart from the electron beam emission unit and which becomes ionized and generates plasma upon being struck by the electron beam. Extreme ultraviolet rays are generated from the plasma.

IPC Classes  ?

• H05G 2/00 - Apparatus or processes specially adapted for producing X-rays, not involving X-ray tubes, e.g. involving generation of a plasma
• G03F 7/20 - Exposure; Apparatus therefor

Abstract

A light source device according to an embodiment of the present invention is a light source device that outputs light from an extreme ultraviolet light source, on the basis of an electron beam and a metal droplet, the light source device comprising: a chamber; an electron beam emitting unit including a cathode electrode and a plurality of emitters including a carbon-based material and disposed on the cathode electrode to be spaced apart from each other, the electron beam emitting unit generating an electron beam inside the chamber; an anode electrode positioned inside the chamber to be spaced apart from the electron beam emitting unit; and a droplet generating device for ejecting metal droplets into a space between the electron beam emitting unit and the anode electrode in the chamber, wherein the droplets are ionized in the chamber by the electron beam directed toward the anode electrode to generate plasma, and extreme ultraviolet rays are generated from the plasma.

IPC Classes  ?

• H05G 2/00 - Apparatus or processes specially adapted for producing X-rays, not involving X-ray tubes, e.g. involving generation of a plasma
• G03F 7/20 - Exposure; Apparatus therefor

Abstract

Agrimonia pilosaGalla rhoisGalla rhois extract as an active ingredient, and does not cause side effects to a human body and thus exhibits excellent safety, and also has excellent antiviral activity due to a cell lesion effect through a virus-dependent pathway, an influenza virus-related gene reducing effect, and the like. Further, the present invention not only is confirmed with an in vivo antiviral effect but also has notably excellent antiviral activity in the active ingredient of the mixed extracts, and thus may be utilized for a composition for preventing, treating or relieving influenza virus infection.

IPC Classes  ?

• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61K 36/22 - Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to a light-emitting layer for an organic light-emitting device, having high efficiency and an organic light-emitting device comprising same and, more specifically, to: a light-emitting layer for an organic light-emitting device, which uses, as a final light emitter, a delayed fluorescent material having a high horizontal orientation ratio and including boron, and thus has improved efficiency and color purity; and an organic light-emitting device comprising same.

IPC Classes  ?

• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof

Abstract

The present invention relates to: a boron compound having a structure comprising a specific substituent; and an organic light-emitting device comprising same, and, more specifically, to a boron compound and an organic light-emitting device comprising same, the boron compound having, attached thereto, a substituent capable of disrupting intermolecular packing at the para-position of boron, which has no effect on color characteristics, and, simultaneously, transforming a boron core inner structure, which affects color characteristics, into a carbazole form having only one side substituted with a heteroatom aromatic ring, so that quantum efficiency and lifespan characteristics are improved.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)

Abstract

The present invention relates to a pore-structured ceramic nanoparticle-carbon allotrope composite and a method for preparing same. According to an embodiment of the present invention, a pore-structured ceramic nanoparticle-carbon allotrope composite can be provided, in which, through the surface modification of ceramic nanoparticles using a polymer containing a polar functional group, the particles are homogeneously distributed in a carbon allotrope.

IPC Classes  ?

• C01B 33/18 - Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof
• C01B 32/198 - Graphene oxide
• C01B 32/194 - After-treatment
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,

Abstract

The present invention provides: a method for manufacturing a graphene light source, the method comprising: forming a graphene layer and electrodes in contact with both sides of the graphene layer; forming a nanogap of the graphene layer; and forming a graphene oxide layer by binding ionized oxygen to a portion of the graphene layer adjacent to one side of the nanogap; an organic light-emitting device comprising the graphene light source; and a method for manufacturing the organic light-emitting device.

IPC Classes  ?

• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• H01L 51/56 - Processes or apparatus specially adapted for the manufacture or treatment of such devices or of parts thereof

Abstract

The present invention relates to an anti-viral composition containing a Panax ginseng-gold nanoemulsion, which contains silydianin. Since it has been identified that a composition containing Panax ginseng-gold nanoparticles and silydianin, of the present invention, has remarkable anti-viral effects, the composition can be effectively used, in the fields of pharmaceuticals, quasi-drugs, foods, cosmetic products and the like, for treatment, prevention, and alleviation of viral diseases or treatment, prevention, and alleviation of inflammatory diseases.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 36/258 - Panax (ginseng)
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

An apparatus for diagnosing a lesion, and a method therefor are provided. An apparatus for diagnosing a lesion, according to several embodiments of the present disclosure, may perform the operations of: acquiring a medical image of a subject; extracting a vascular region from the acquired medical image; measuring the distance between vascular bifurcations in the extracted vascular region; and predicting the size of a lesion on the basis of the measured distance. Therefore, the size of a lesion can be accurately predicted even without the intervention of a person.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
• A61B 1/31 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the rectum, e.g. proctoscopes, sigmoidoscopes
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation

Abstract

Provided is a method for manufacturing small and uniform light-emission type organic nanoparticles with improved yield. The method for manufacturing light-emission type organic nanoparticles according to the present invention comprises the steps of: (S1) preparing a first mixture by mixing an organic phosphor and a surfactant; and (S2) preparing a dispersion by mixing the first mixture with a first solvent which is an anti-solvent for the organic phosphor.

IPC Classes  ?

• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• H01L 27/32 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including components using organic materials as the active part, or using a combination of organic materials with other materials as the active part with components specially adapted for light emission, e.g. flat-panel displays using organic light-emitting diodes

Abstract

The present invention provides an optical device and an operation method thereof, the optical device comprising: a substrate; an optical waveguide extending in a first direction on the substrate; and a ring resonator adjacent to the optical waveguide in a second direction crossing the first direction on the substrate, wherein: the ring resonator comprises first and second graphene layers on the substrate, a first insulating layer between the substrate and the first graphene layer, a second insulating layer between the first graphene layer and the second graphene layer, first and second electrodes connected to the first graphene layer, and a third electrode connected to the second graphene layer; and the first and second graphene layers and the first and second insulating layers have a ring shape or a partially open ring shape.

IPC Classes  ?

• G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means

Abstract

The present invention relates to a compound having therapeutic activity for total inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. An ergostenol or cholestenol derivative compound according to the present invention exhibits excellent anti-inflammatory and colitis amelioration effects, and thus has an excellent therapeutic effect on inflammatory bowel diseases.

IPC Classes  ?

• C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention relates to a composition containing vascular endothelial progenitor cells and mesenchymal stem cells as active ingredients for prevention or treatment of occlusive vascular diseases or complications thereof. Since it was found that vascular endothelial progenitor cells and mesenchymal stem cells remarkably improved vascularization ability upon application thereof in combination, the present invention has the effect of providing a new cell therapy product for prevention or treatment of occlusive vascular diseases or ulcers resulting therefrom, and a preparation method therefor.

IPC Classes  ?

• A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating obesity, wherein the pharmaceutical composition contains Polygalin C as an active ingredient. The Polygalin C not only reduces the accumulation of lipids by inhibiting the differentiation of preadipocytes into adipocytes, but also inhibits adipogenic factors and modulates AMPK/ACC and MAPK/Akt signaling pathways to inhibit the differentiation of adipocytes, and thus can treat obesity more effectively. In addition, the present invention inhibits adipogenic factors and inflammatory factors in a free fatty acid-induced non-alcoholic steatohepatitis (NASH) cell model, and thus can effectively treat and prevent non-alcoholic fatty liver disease (NAFLD) including hepatic steatosis and non-alcoholic steatohepatitis.

IPC Classes  ?

• A61K 36/69 - Polygalaceae (Milkwort family)
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/04 - Anorexiants; Antiobesity agents

Abstract

The present invention relates to an anticancer agent capable of overcoming EGFR-TKI resistance in KRAS mutant cancer. GW8510 according to the present invention is an effective inhibitor against oncogene mutation, especially, KRAS mutation, generated in cancer resistant to the anticancer agent EGFR inhibitor and remarkably inhibits expression of both the wild-type and various mutants of KRAS, whereby the drug itself exhibits an anticancer effect, surmounts anticancer resistance, and noticeably promotes the death of anticancer-resistant cancer cells when used in combination with an anticancer agent. Thus, the inhibitor finds advantages applications in treating cancer, especially resistant cancer.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Abstract

The present invention relates to a composition for diagnosing diabetes, comprising a substance for detecting metabolites in tears isolated from a diabetic patient, or a method for providing information for diagnosing diabetes. According to the present invention, metabolites showing higher or lower levels than a control have been identified through GC/TOF MS analysis of the tears of diabetic patients, and the case in which the level of threonine, pentadecanoic acid, mannose, threose, sorbitol, serine, alanine or squalene is higher than that of the control, or the case in which the level of 1,5-anhydroglucitol or beta-alanine is lower than that of the control, can be diagnosed as having a high possibility of developing diabetes, as compared to the control.

IPC Classes  ?

• G01N 30/72 - Mass spectrometers
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups

Abstract

The present invention relates to a method for preparing bone-marrow-derived endothelial progenitor cells having increased vasculogenesis by using PDGF-BB, and a method for preparing a cell therapeutic agent for treating anangioplasia-related diseases by using the method. Particularly, the present invention relates to: a method for preparing endothelial progenitor cells having increased vasculogenesis, comprising a step of treating isolated endothelial progenitor cells with PDGF-BB and culturing same; a composition for stimulating vasculogenesis, comprising endothelial progenitor cells and PDGF-BB as active ingredients; a method for preparing a cell therapeutic agent for treating anangioplasia-related diseases, comprising a step of mixing isolated endothelial progenitor cells, mesenchymal stem cells and PDGF-BB; and a cell therapeutic agent for treating anangioplasia-related diseases, prepared by the method.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/18 - Growth factors; Growth regulators
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present invention relates to a virtual sensor device for a fluid-solid soft structure and an operation method thereof. The virtual sensor device according to an embodiment comprises: an experiment data acquisition part for acquiring modal data derived through a modal experiment with regard to a fluid-solid soft structure; a physical model update part for updating a physical model for simulating the fluid-solid soft structure by using an order reduction modeling method and the acquired modal data; an actual measurement data measurement part for measuring actual measurement displacement data from a first point of the fluid-solid soft structure; and a virtual sensor information generation part for estimating virtual displacement data at a second point of the fluid-solid soft structure by using the updated physical model, the measured actual measurement displacement data, and a virtual sensing algorithm, and generating virtual sensor information at the second point on the basis of the estimated virtual displacement data.

IPC Classes  ?

• G05B 23/02 - Electric testing or monitoring
• G01D 21/02 - Measuring two or more variables by means not covered by a single other subclass

Abstract

Provided is a real needle set for a double-blind test, having an improved structure such that it is difficult for a subject and an operator to distinguish whether a needle being used is a real needle or a fake needle when the treatment effects of acupuncture are studied. A real needle set for a double-blind test, according to one embodiment of the present invention, may comprise: a support member having one surface coming in contact with the skin of a subject, and having a through-hole formed in the vertical direction; a filling member coupled in the through-hole of the support member, and provided in a pipe shape of which one side is shielded; a hollow guide member of which a portion of the lower side is coupled in the through-hole of the support member and which has a first guide protrusion protruding therein; and a moving member which moves in the vertical direction in the guide member while coupled to a needle body, and which has a portion that is caught by the first guide protrusion so as to guide the start of acupuncture and that passes through the first guide protrusion so as to be loaded on the upper end of the guide member during acupuncture, so that the needle body is guided to penetrate the filling member and the skin of the subject.

IPC Classes  ?

• A61H 39/08 - Devices for applying needles to such points, i.e. for acupuncture
• A61B 17/34 - Trocars; Puncturing needles
• A61H 39/00 - Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture

Abstract

Proteus mirabilisProteus mirabilis strain, from a biological sample of a subject. The present invention also relates to a method for providing information for diagnosing a neurodegenerative disease such as Parkinson's disease, cranial neuritis or Alzheimer's disease, by measuring the amount of hpmA.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
• A01K 67/027 - New breeds of vertebrates

Abstract

The present invention relates to: a food composition, a cosmetic composition, and a feed composition for alleviation of hair loss or promotion of hair regrowth, and a pharmaceutical composition for prevention or treatment of a hair loss disease, each composition comprising an Euphrasia pectinata extract; a method for prevention or treatment of a hair loss disease, the method comprising a step of administering to a subject a composition comprising a Euphrasia pectinata extract as an active ingredient; and a use of a food composition, a cosmetic composition, and a feed composition for alleviating hair loss or promoting hair regrowth, and a use of a pharmaceutical composition for preventing or treating a hair loss disease, each composition comprising an Euphrasia pectinata extract. The Euphrasia pectinata extract of the present invention increases the growth rate of human body-derived dermal papilla cells to exhibit excellent effects of alleviating hair loss and promoting hair regrowth and as such, can be utilized in drugs, foods, health functional foods, cosmetics, and so on which are effective for prevention and treatment of hair loss.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 7/00 - Preparations for affecting hair growth
• A61K 36/64 - Orobanchaceae (Broom-rape family)
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A23K 10/30 - Animal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention provides a medicinal and/or culinary use of an Artemisia annua extract for treating, ameliorating and/or preventing at least one selected from among bone diseases, menopausal disorders, cardiovascular diseases, neurodegenerative diseases, and obesity. The present invention has the advantage of having little or no possibility of side effects such as cancer, and being capable of effectively treating, ameliorating and/or preventing at least one selected from among bone diseases, menopausal disorders, cardiovascular diseases, neurodegenerative diseases, and obesity.

IPC Classes  ?

• A61K 36/282 - Artemisia, e.g. wormwood or sagebrush
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 15/12 - Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 3/04 - Anorexiants; Antiobesity agents

Abstract

The present invention relates to a pharmaceutical composition for enhancing melanoma metastasis treating effect. More particularly, it has been confirmed that the melanoma preventing or treating effect of dabrafenib was notably enhanced when the composition comprising the oligodendrocyte transcription factor 2 (OLIG2) inhibitor was concomitantly administered with dabrafenib. The pharmaceutical composition of the present invention enables effective treatment of melanoma even when less dabrafenib is used than an existing dose, and thus can be free from the problem of toxicity and side effects.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an operation method of a MEC device for providing an Internet of Vehicles (IoV) application service, comprising the steps of: receiving, from vehicle communication nodes, meta data of images captured by means of each of the vehicle communication nodes; determining, on the basis of the received meta data of the images, image data to be requested from at least some vehicle communication nodes from among the vehicle communication nodes; transmitting, to at least some vehicle communication nodes, information about the images to be requested; receiving the requested images from at least some of the vehicle communication nodes; and storing, in a database, the images received from at least some of the vehicle communication nodes.

IPC Classes  ?

• H04L 29/08 - Transmission control procedure, e.g. data link level control procedure
• G06T 7/00 - Image analysis
• G06T 5/50 - Image enhancement or restoration by the use of more than one image, e.g. averaging, subtraction
• G06F 16/583 - Retrieval characterised by using metadata, e.g. metadata not derived from the content or metadata generated manually using metadata automatically derived from the content
• G06F 16/23 - Updating
• G06F 16/16 - File or folder operations, e.g. details of user interfaces specifically adapted to file systems

Abstract

The present invention relates to a polystyrene sulfonate metal salt, a production method thereof, and a composition including same, and more specifically, to a polystyrene sulfonate metal salt represented by formula 1, a production method thereof, and a composition including same.

IPC Classes  ?

• C08F 12/30 - Sulfur
• C08F 8/42 - Introducing metal atoms or metal-containing groups
• C08L 25/18 - Homopolymers or copolymers of aromatic monomers containing elements other than carbon and hydrogen

Abstract

The present invention relates to a composition comprising a polystyrene sulfonic acid metal salt, a semiconductor device, and a method for manufacturing same, and more specifically, to a composition comprising: a polystyrene sulfonic acid metal salt; and an anionic polyelectrolyte, a semiconductor device comprising the composition, and a method for manufacturing same.

IPC Classes  ?

• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
• H01L 51/56 - Processes or apparatus specially adapted for the manufacture or treatment of such devices or of parts thereof

Abstract

The present invention relates to a composition, for preventing, relieving or treating cancer cachexia or muscle loss, containing Uchasingi-hwan. The Uchasingi-hwan of the present invention exhibited a weight loss relieving effect in a cancer cachexia-induced mouse model, inhibits IL6, CRP and TNF-α expression, inhibits an increase in MURF1 and MAFbx expression in muscle tissues, and inhibits a decrease in the muscle tissue size, and thus can be utilized in a composition for preventing, relieving or treating cancer cachexia or muscle loss.

IPC Classes  ?

• A61K 36/804 - Rehmannia
• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61K 36/40 - Cornaceae (Dogwood family)
• A61K 36/8945 - Dioscorea, e.g. yam, Chinese yam or water yam
• A61K 36/68 - Plantaginaceae (Plantain Family)
• A61K 36/884 - Alismataceae (Water-plantain family)
• A61K 36/076 - Poria
• A61K 36/71 - Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
• A61K 36/54 - Lauraceae (Laurel family), e.g. cinnamon or sassafras
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating epilepsy, the composition comprising gintonin as an active ingredient. Gintonin of the present invention has the effects of: reducing seizure behavior in a temporal lobe epilepsy animal model in which apoptosis of excitatory neurons is induced by kainic acid; and significantly inhibiting apoptosis of hippocampal neurons, activity of microglial cells and astrocytes, and the expression of COX-2 and iNOS that are representative inflammation mediators. Accordingly, the composition comprising gintonin of the present invention may be useful as a composition for preventing, treating, or ameliorating epilepsy.

IPC Classes  ?

• A61K 38/14 - Peptides containing saccharide radicals; Derivatives thereof
• A61K 36/258 - Panax (ginseng)
• A61P 25/08 - Antiepileptics; Anticonvulsants
• A23L 33/185 - Vegetable proteins

Abstract

Provided are a system and a method for performing layer optimization of a stacked resistive random access memory device by using artificial intelligence technology. The method relates to a method using a neural network device for performing layer optimization of a stacked resistive random access memory device by using artificial intelligence technology, and may comprise the steps of: classifying, by the neural network device, BNN parameters into a physical parameter and a hyper-parameter in a BNN model; obtaining, by the neural network device, an optimal parameter by using the physical parameter and the hyper-parameter; and calculating, by the neural network device, a minimum channel size in the BNN model by using the optimal parameter.

IPC Classes  ?

• G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
• G06N 3/08 - Learning methods
• G06N 3/04 - Architecture, e.g. interconnection topology

Abstract

Provided according to the present invention is a software defined network (SDN)-based slicing method in a hierarchical cluster unmanned aerial vehicle (UAV) network. The method is performed by a particular UAV within a UAV network, the method comprising: a network monitoring step of collecting monitoring information for controlling a UAV switch of a slicing path via an SDN UAV; a network slicing step of slicing the UAV network according to the collected monitoring information; and a reinforced learning step of performing reinforced learning for UAV relocation within the sliced UAV network, such that the UAV, when deployed as a communication resource, can provide service of a better quality with respect to each requirement of the service compared to the service provided when simply deployed.

IPC Classes  ?

• H04W 24/02 - Arrangements for optimising operational condition
• H04W 40/12 - Communication route or path selection, e.g. power-based or shortest path routing based on transmission quality or channel quality
• H04W 40/24 - Connectivity information management, e.g. connectivity discovery or connectivity update
• H04W 72/10 - Wireless resource allocation based on priority criteria
• H04W 84/20 - Master-slave arrangements
• H04W 84/06 - Airborne or Satellite Networks
• H04W 4/40 - Services specially adapted for particular environments, situations or purposes for vehicles, e.g. vehicle-to-pedestrians [V2P]
• G06N 20/00 - Machine learning

Abstract

The present specification relates to a delayed fluorescence compound represented by chemical formula 1 and an organic light-emitting device comprising same, and achieves delayed fluorescence light sensitive hyperfluorescence properties by the use of a compound that exhibits deep blue properties and has a low singlet-triplet energy difference, and a fluorescent compound which, relative to conventional delayed fluorescence material, exhibits deep blue properties, has a narrow half-width, and has excellent colour purity.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)

Abstract

The present invention relates to a fluorescent probe for detecting adenosine triphosphate and a use thereof, wherein the fluorescent probe can selectively detect adenosine triphosphate without interference from in vivo molecules having a similar structure. In addition, the fluorescent probe according to the present invention has the advantages of having a simple structure and enabling fast mass synthesis. The fluorescent probe according to the present invention has the form of a nanoparticle in an aqueous solution and selectively exhibits fluorescence turn-on properties when bound to adenosine triphosphate, and thus not only overcomes the problems of existing fluorescent probes having a complex structure for detecting adenosine triphosphate and problems due to interference from molecules having a similar structure to adenosine triphosphate, but also has the advantages of high sensitivity and selectivity, fast reaction time, and having wide applicability, such as in the detection of adenosine triphosphate in mitochondria in cells, and thus can be efficiently utilized for selective detection and imaging.

IPC Classes  ?

• C07C 211/52 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

12122| ≤ 0.2 eV, the binding energy of the first compound in an anion state being lower than the binding energy of the second compound in an anion state; and a delayed fluorescence sensitized hyperfluorescence device further comprising a third compound, which is a delayed fluorescence or fluorescent compound. A host, which has excellent electron transport capacity to have a LUMO energy level similar to that of a delayed fluorescence dopant, is used to delay the deterioration of a delayed fluorescence compound, and thus the lifespan of a delayed fluorescence organic light-emitting device or a hyperfluorescence organic light-emitting device can be remarkably improved.

IPC Classes  ?

• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof

Abstract

The present invention relates to a top-down manufacturing method for nanowires using monocrystalline silicon and, more particularly, to a manufacturing method in which horizontally arranged single-layered silicon-nanowire arrays are stacked vertically. The present invention enables the widths and thicknesses of silicon nanowires to be adjustable and the plurality of nanowires to be vertically arranged, thereby improving dynamic range, resolution, and sensitivity when the nanowires are used as a sensor (light, chemical, physical, etc.).

IPC Classes  ?

• H01L 21/3065 - Plasma etching; Reactive-ion etching
• G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
• H01L 21/308 - Chemical or electrical treatment, e.g. electrolytic etching using masks
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof

Abstract

The present invention relates to a composition for preventing, ameliorating or treating cachexia, comprising a complex extract of Salviae miltiorrhizae radix and Rhei radix et rhizoma, wherein the complex extract suppresses weight loss and fat loss caused by cancer, and induces cancer cell death, and thus, can be useful as a composition for preventing, ameliorating, or treating cancer cachexia, the composition enabling anti-cancer treatment without cachexia side effects and cachexia amelioration simultaneously.

IPC Classes  ?

• A61K 36/537 - Salvia (sage)
• A61K 36/70 - Polygonaceae (Buckwheat family), e.g. spineflower or dock
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present specification relates to a boron compound represented by chemical formula 1 and an organic light-emitting device including same, wherein the compound has an emission spectrum with a narrow full width at half maximum, compared to a delayed fluorescence material of the prior art, and excellent internal quantum efficiency, and thus has high color purity and high efficiency characteristics.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)

Abstract

The present invention relates to: a pharmaceutical composition for preventing or treating cachexia, containing Bojungikgitang, an extract thereof or a fraction thereof; a method for preventing or treating cachexia, comprising a step of administering the pharmaceutical composition; and a food composition or feed composition for preventing or alleviating cachexia, containing Bojungikgitang, an extract thereof or a fraction thereof. The pharmaceutical composition for preventing or treating cachexia, provided in the present invention, contains Bojungikgitang, which is conventionally used and has proved safety, and thus can be widely used in the development of a pharmaceutical composition for treating various forms of muscular atrophy and sarcopenia, which are caused by carcinemia.

IPC Classes  ?

• A61K 36/481 - Astragalus (milkvetch)
• A61K 36/284 - Atractylodes
• A61K 36/258 - Panax (ginseng)
• A61K 36/232 - Angelica
• A61K 36/233 - Bupleurum
• A61K 36/725 - Ziziphus, e.g. jujube
• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 36/71 - Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a composition for preventing, ameliorating or treating cachexia, comprising a complex extract of Cyperi rhizoma and Zanthoxyli pericarpium. The complex extract of the present invention exhibits the effects of suppressing weight loss and fat loss caused by cancer and inducing cancer cell death, and thus can be useful as a composition for preventing, ameliorating or treating cancer cachexia, the composition enabling anticancer treatment without cachexia side effects and cachexia amelioration simultaneously.

IPC Classes  ?

• A61K 36/8905 - Cyperus (flatsedge)
• A61K 36/74 - Rubiaceae (Madder family)
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 35/00 - Antineoplastic agents
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

Disclosed is a biomaterial that is for tissue regeneration and has multiple physical properties. The biomaterial for tissue regeneration according to an embodiment of the present invention consists of single cells, wherein the single cells include a first region cultured by receiving a single stimulus and a second region positioned within the first region and cultured by receiving complex stimuli, and have multiple physical properties.

IPC Classes  ?

• A61L 27/38 - Animal cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention relates to a composition for the diagnosis and treatment of Parkinson's disease, comprising a neuropeptide and a neurotrophin. Through having found the fact that the mRNA and protein expression of neuropeptides CCK and Dyn A and neurotrophin BDNF were reduced in the intestines of a mouse model in which Parkinson's disease was induced, it has been confirmed that the intestinal neuropeptides and neurotrophin can be used for the diagnosis of Parkinson's disease. The use of neuropeptides and a neurotrophin, for diagnosing and treating Parkinson's disease, according to the present invention, may be the diagnosis of Parkinson's disease showing early symptoms that could not have been diagnosed by existing diagnosis methods, and due to an excellent therapeutic effect on Parkinson's disease, may be effective in the diagnosis or treatment of Parkinson's disease.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a novel salt compound and a use thereof. It has been revealed that when a salt compound of the present invention is treated, the growth of Candida spp. is inhibited and cytolysis occurs, and thus it has been ascertained that the salt compound of the present invention can be used for an anti-fungal purpose so that candidiasis caused by Candida spp can be treated. The novel salt compound of the present invention has the excellent effect of inhibiting the growth of Candida spp when compared to conventional anti-fungal agents, and has an anti-fungal effect on fungi having resistance to conventional anti-fungal agents, and thus can be effectively used in the alleviation or treatment of candidiasis.

IPC Classes  ?

• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/10 - Antimycotics

Abstract

The present invention relates to a composition comprising an Atractylodes macrocephala and Agastache rugosa mixed extract for alleviating fatigue or enhancing exercise performance. The composition comprising an Atractylodes macrocephala and Agastache rugosa mixed extract as an active ingredient, according to the present invention, increases the expression of PGC-1 alpha and enhances exercise performance through a decrease in serum, muscular lactic acid, and serum lactate dehydrogenase levels following physical activities, thereby effectively alleviating accumulated fatigue and enhancing exercise performance and, as such, can be applied to a food composition, a pharmaceutical composition, and a cosmetic composition for alleviating fatigue or enhancing exercise performance and to a pharmaceutical composition for preventing or treating disease associated with fatigue or exercise performance.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 19/00 - Products from fruits or vegetables; Preparation or treatment thereof
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A61K 36/284 - Atractylodes
• A61K 36/532 - Agastache, e.g. giant hyssop
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a composition for inducing browning, a pharmaceutical composition for preventing or treating metabolic diseases, and a food composition for alleviating metabolic diseases, all of the compositions containing milk exosomes. In addition, the present invention relates to a method for inducing the differentiation of white adipocytes into beige adipocytes or brown adipocytes by treating the milk exosomes, and a method for treating obesity or metabolic diseases by administering the milk exosomes.

IPC Classes  ?

• A61K 35/20 - Milk; Whey; Colostrum
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention relates to a composition for the prevention, amelioration or treatment of inflammatory diseases or immune diseases, the composition comprising as an active ingredient, Gancaonin N, which is a flavonoid ingredient derived from the root and aerial part of Glycyrrhiza aspera Pall. According to the present invention, it has been confirmed that Gancaonin N, which is a flavonoid ingredient derived from the root and aerial part of Glycyrrhiza aspera Pall, inhibits the production of nitric oxide (NO), which is an important factor in inducing inflammation, inhibits the expression of PGE2, iNOS, and COX-2, which are known factors that induce inflammation, and exhibits no cytotoxicity. Thus, the composition comprising Gancaonin N as an active ingredient, according to the present invention, can be effectively used as a safe and natural therapeutic agent for inflammatory diseases and immune diseases with fewer side effects, particularly as a therapeutic agent for lung inflammation.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 36/484 - Glycyrrhiza (licorice)

Abstract

The present invention relates to an organic light-emitting device and a method for manufacturing same, and an organic light-emitting device according to an embodiment includes: a substrate on which at least one nano-island structure is formed; and an organic light-emitting structure formed on the substrate, wherein, as the substrate, an inorganic material layer is formed, and the formed inorganic material layer is exposed to an environment including a preset temperature and humidity conditions to form nano-island structures.

IPC Classes  ?

• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
• H01L 51/52 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED) - Details of devices

Abstract

In the present invention, among blood metabolites, amino acids, organic compounds and oxylipins that were statistically significantly differentiated from the control group, were selected from type 2 diabetes patients. Specifically, asparagine, aspartic acid, glutamic acid, cysteine, lysine, citric acid, and uric acid, and 12-oxo ETE, 15-oxo ETE, 9-oxo ODE, and 20-carboxy leukotriene B4, which are oxylipins, were confirmed to have cutoff values of AUC>0.7. In addition, the blood metabolites showed a significant difference between a DME patient group and a non-DME patient group, and thus were confirmed to be usable for accurate diagnosis of DME.

IPC Classes  ?

• G01N 30/72 - Mass spectrometers
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to a microfluidic device, and a sample analysis apparatus using the microfluidic device. According to one embodiment, a microfluidic device comprises a rotating body and at least one microfluidic structure arranged at preset intervals in the rotating body, wherein the microfluidic structure shares, with a different adjacent microfluidic structure, through a shared channel, a solution injected through a solution injection port, and may include: a pretreatment part for pretreating the solution and a sample, which is injected through a sample injection port; a storage part which is positioned to be further outside, than the pretreatment part, in the radial direction in the rotating body, and which separates and stores, according to the rotational direction of the rotating body, the sample and solution pretreated through the pretreatment part; and a detection part to which target materials in the pretreated sample are distributed from the storage part and through which detection is performed on the distributed target materials.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

Abstract

The present invention relates to a novel compound which exhibits the effect of treating, preventing, or ameliorating lymphedema, and a composition comprising same as an active ingredient, the composition being applied as medicines, functional foods or food supplements, or cosmetics. The active ingredient compound according to the present invention exhibits a significant improvement effect on lymphedema in various terms such as TNFα production inhibitory activity, metabolic stability, solubility, and exposure in blood.

IPC Classes  ?

• C07C 49/223 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the aromatic rings polycyclic
• C07D 311/74 - Benzo [b] pyrans, hydrogenated in the carbocyclic ring
• A61K 31/12 - Ketones
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 7/10 - Antioedematous agents; Diuretics
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to an organic light-emitting diode comprising nano-island structures and a method for manufacturing same. An organic light-emitting diode according to an embodiment comprises: a substrate provided with a plurality of nano-island structures; and a light-emitting structure formed on the substrate, wherein the nano-island structures are formed through a dewetting process of an inorganic layer deposited on the substrate, and the diameter and height thereof may be determined by at least one of the thickness of the deposited inorganic layer, and temperature and humidity conditions in the dewetting process.

IPC Classes  ?

• H01L 51/52 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED) - Details of devices
• H01L 51/56 - Processes or apparatus specially adapted for the manufacture or treatment of such devices or of parts thereof

Abstract

The present invention pertains to a composition for preventing, ameliorating, or treating metabolic diseases, the composition containing Jujuboside A as an active ingredient. Jujuboside A according to the present invention effectively differentiates white adipocytes into beige adipocytes through a browning process, and can thus be applied to various industries for the purpose of preventing, ameliorating, or treating diseases such as metabolic diseases.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/00 - Drugs for disorders of the metabolism
• A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
• A23K 20/163 - Sugars; Polysaccharides
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention relates to a fibrocartilage preparation method and fibrocartilage prepared by the method.

IPC Classes  ?

• A61L 27/38 - Animal cells
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

Abstract

The present invention relates to a negative active material for a lithium secondary battery, a lithium secondary battery having same, and a manufacturing method thereof. The present invention is to improve high-rate charging characteristics without deterioration of charging/discharging efficiency and lifespan characteristics when applied as a negative active material of a lithium secondary battery by forming a coating layer containing self-bound porous carbon particles on the surface of a carbon-based material, thereby reducing resistance during insertion of lithium ions on the surface of the carbon-based material and improving reactivity and structural stability of the surface. The negative active material according to the present invention includes a carbon-based material, and a porous carbon coating layer self-bound to the surface of the carbon-based material. In this case, a self-bound amorphous carbon coating layer can selectively control a pore structure through chemical etching.

IPC Classes  ?

• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• C01B 32/21 - After-treatment

Abstract

An extreme-ultraviolet light source device comprises: a discharge chamber of which the inside is maintained in a vacuum; an electron beam-emitting unit which is located inside the discharge chamber and produces electron beams; and a metal radiator which is located inside the discharge chamber and is ionized by the electron beams. Extreme-ultraviolet radiation occurs in plasma generated from the metal radiator. The electron beam-emitting unit comprises: a cathode electrode; a plurality of emitter located on the cathode electrode and comprising a carbon-based material; and a gate electrode which is located on the plurality of emitters with a distance therefrom and to which a pulse voltage is applied.

IPC Classes  ?

• H05G 2/00 - Apparatus or processes specially adapted for producing X-rays, not involving X-ray tubes, e.g. involving generation of a plasma

Abstract

The present invention relates to a low specific gravity microcarrier-based cell culture device and a method for monitoring cell culture using same and, more specifically, to four-dimensional cell culture having the characteristics of monitoring the growth state of cells by reflecting a time factor to three-dimensional cell culture, and being capable of stable cell expansion culture by minimizing changes in the cell characteristics.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/09 - Flotation apparatus
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/26 - Inoculator or sampler
• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/00 - Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials

Abstract

The present invention relates to a virus-blocking composition comprising sodium phosphate, and a virus-blocking mask filter comprising the composition.

IPC Classes  ?

• A01N 59/08 - Alkali metal chlorides; Alkaline earth metal chlorides
• A01N 59/26 - Phosphorus; Compounds thereof
• A41D 13/11 - Protective face masks, e.g. for surgical use, or for use in foul atmospheres

Abstract

Disclosed is a method for selecting a gene. To this end, the method comprises the steps of: acquiring gene expression level data and a phylogenetic tree on the basis of the protein sequence of genes of a subject; if a specific gene input as a query is included among genes sharing the same domain in the phylogenetic tree, determining a correlation by comparing the expression pattern of the specific gene and the expression patterns of each of the genes in the phylogenetic tree; determining a target gene having an overlapping function with the specific gene among the genes of the subject, on the basis of the correlation determined for said specific gene; and providing information about the determined target gene.

IPC Classes  ?

• G16B 40/20 - Supervised data analysis
• G16B 30/10 - Sequence alignment; Homology search
• G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
• G16B 45/00 - ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks

Abstract

An embodiment of the present invention provides a hydrogen generation reaction catalyst and a catalyst composite comprising same, wherein the catalyst comprises a dendrimer and a nanoparticle encapsulated in the dendrimer, the nanoparticle being composed of an alloy of platinum and palladium, whereby the catalyst can reduce activation energy for hydrogen generation.

IPC Classes  ?

• B01J 37/02 - Impregnation, coating or precipitation
• B01J 35/02 - Solids
• B01J 23/44 - Palladium
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia

Abstract

The present invention relates to: a composition for differentially diagnosing acanthamoeba keratitis, the composition comprising chorismate mutase antibodies; and an acanthamoeba keratitis diagnosis kit using same. The composition comprising chorismate mutase antibodies according to the present invention causes an antigen-antibody reaction only specific to chorismate mutase secreted from acanthamoeba, thus making it possible to diagnose and identify the cause of acanthamoeba keratitis more rapidly and accurately than existing methods for diagnosing acanthamoeba keratitis. The composition is expected to be widely applicable to the production of acanthamoeba keratitis diagnosis kits, therapeutic agents, contact lens disinfecting agents, etc.

IPC Classes  ?

• G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a composition comprising a Rosa laevigata fruit extract for prevention, treatment, or alleviation of a respiratory disease. In the present invention, a Rosa laevigata fruit extract was identified to have an anti-inflammatory effect and a therapeutic effect on laryngitis, bronchitis, or respiratory diseases on the basis of the finding that a composition comprising a Rosa laevigata fruit extract inhibits an inflammation-related signaling pathway and reduces the release of inflammatory factors and inflammatory cytokines. Hence, the Rosa laevigata fruit extract according to the present invention can be advantageously used for prevention, treatment, or alleviation of respiratory diseases.

IPC Classes  ?

• A61K 36/738 - Rosa (rose)
• A61P 11/00 - Drugs for disorders of the respiratory system
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to a method for producing an ADM collagen fiber, an ADM collagen fiber produced thereby, and an apparatus for producing an ADM collagen fiber, and more particularly, to a method for producing an ADM collagen fiber, the method comprising a step for extruding an acidic ADM collagen solution into a basic solution to form a filament. According to the present invention, there is an effect of providing: a method for producing an ADM collagen fiber; an ADM collagen fiber produced thereby; and an apparatus for producing an ADM collagen fiber, wherein a collagen solution raw material of a desired concentration can be prepared by directly crushing an ADM collagen shell, and thus the manufacturing cost and time are minimal and economic efficiency and productivity are high, mass production is possible with a continuous process apparatus having a simple structure, and ADM collagen fibers of various thicknesses and properties and having a high degree of usefulness can be produced due to the wide concentration range of the collagen solution raw materials that can be used. [Representative drawing] figure 1

IPC Classes  ?

• D01F 4/00 - Monocomponent artificial filaments or the like of proteins; Manufacture thereof
• D01D 5/06 - Wet spinning methods
• D01D 10/06 - Washing or drying
• D01F 1/10 - Other agents for modifying properties

Abstract

The present invention relates to nanoparticles for delivering a brain cancer cell-targeting drug which is surface-treated with a peptide for targeting brain cancer cells, a method for preparing same, and use thereof and, more particularly, to nanoparticles for delivering a brain cancer cell-targeting drug, a method for preparing same, and use of the nanoparticles for brain cancer treatment, the nanoparticles comprising: porous silicon nanoparticles in which an anti-cancer drug is encapsulated; and a peptide which is bound to the surfaces of the nanoparticles and has the ability to target brain cancer cells. The nanoparticles according to the present invention enable the specific delivery of conventional anti-cancer drugs that exhibit low tissue specificity and solubility, to caveolin receptor-overexpressing glioblastoma by passing through the blood-brain barrier, thereby inducing a more efficient effect of treating glioblastoma, and thus can be used as an effective drug carrier for glioblastoma treatment. Thus, the nanoparticles improve the efficiency of anti-cancer drugs with poor in-vivo distribution and can be applied to the treatment of caveolin-overexpressing cancer cells, and therefore, are expected to be effectively used in clinical anti-cancer research fields.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61P 35/00 - Antineoplastic agents